Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3525 USD | +2.78% | +3.80% | +109.82% |
Apr. 02 | Transcript : BioLargo, Inc., Q4 2023 Earnings Call, Apr 02, 2024 | |
Apr. 01 | BioLargo, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+109.82% | 104M | - | ||
+5.14% | 103B | A- | ||
-5.63% | 63.04B | A- | ||
+39.52% | 39.06B | B | ||
+12.91% | 37.58B | B | ||
+7.41% | 33.24B | A- | ||
+6.85% | 19.22B | B- | ||
+12.86% | 16.83B | C+ | ||
+16.93% | 14.96B | B- | ||
+7.73% | 15.03B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- BLGO Stock
- Ratings BioLargo, Inc.